Skip to main content
Evidence Snapshot

Cruzipain

CHEMBL3563 SINGLE PROTEIN Trypanosoma cruzi
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3563
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cruzipain as ChEMBL target CHEMBL3563, mapped to UniProt P25779. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cruzipain
SINGLE PROTEIN · Trypanosoma cruzi
As of 2026-09-13
ChEMBL target ID
CHEMBL3563
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25779
Cruzipain
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cruzipain matters

As of 2026-09-13

Cruzipain is reviewed as Cruzipain (UniProt P25779); the current evidence base includes 11 approved drugs, 30258 compounds, and 324 assays, with lead potency reaching pChEMBL 10.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 30258 compounds, and 324 assays for this target. The dominant activity type is IC50. CHEMBL4596414 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL4596414 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 10.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cruzipain matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P25779, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

30258
Total Compounds
324
Total Assays
11
Approved Drugs
IC50: 1048.0, KI: 363.0, KD: 2.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4596414
 10.1 IC50 —
No preferred name
CHEMBL4594870
 10.1 IC50 —
No preferred name
CHEMBL4596647
 10.1 IC50 —
No preferred name
CHEMBL1290084
 10.0 IC50 —
No preferred name
CHEMBL3558756
 10.0 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:22Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3563